Michael A Metzger has sold stock and made no open-market buys since Nov 2020

Michael A. Metzger is a seasoned biopharmaceutical executive and Chief Executive Officer of Syndax Pharmaceuticals Inc. (SNDX), a publicly traded oncology-focused biotechnology company.( He assumed the CEO role in 2022 after serving as Syndax’s President and Chief Operating Officer since 2015 and has been a member of the company’s Board of Directors since 2019.( Under his leadership, Syndax has advanced and launched multiple oncology therapies, including recent dual drug approvals that have strengthened the company’s position in redefining cancer care.(

Prior to joining Syndax, Metzger held several senior leadership roles across the life sciences industry, including President and CEO of Regado Biosciences, where he guided the company through a merger with Tobira Therapeutics, and Executive Vice President and Chief Operating Officer at Mersana Therapeutics, overseeing key strategic initiatives in antibody-drug conjugate development for oncology.( Earlier in his career, he worked in business development and M&A at Forest Laboratories, held leadership positions at Onconova Therapeutics, and served as Managing Director at healthcare-focused venture capital firm MESA Partners.( Metzger has served on multiple public and private company boards, including CTI BioPharma Corp., and holds a B.A. from George Washington University and an M.B.A. in Finance from the NYU Stern School of Business.(

Written by Perplexity from public sources.